| abstract |
Compounds of formula (I), wherein Ar, n, R1, R2, R3 and R4 are defined in the specification, as well as pharmaceutically acceptable prodrug derivatives and pharmaceutically acceptable salts thereof, exhibit valuable pharmaceutical properties, especially as inhibitors of TNF-alpha activity and of matrix-degrading metalloproteinases. Therefore, they can be used in the treatment of a large spectrum of diseases, e.g. as antiinflammatory agents for the treatment of e.g. osteoarthritis, rheumatoid arthritis, or as antitumor agents e.g. for the treatment and prevention of tumor growth, tumor metastasis, tumor invasion or progession. They are prepared in a manner known per se. |